Full Press Release Details
Biotechnology Announces $2.25 Million Private Placement
IL - September 29, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage
biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements
for the purchase and sale of an aggregate of 1,733,766 shares of common stock at a purchase price of $1.30 per share, in a private placement
to accredited investors and a Company director. Each share of common stock is being offered together with a warrant to purchase one share
of common stock at an exercise price of $1.57 per share, which price represents the "Minimum Price" as defined under NYSE
American Rule 713 (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six-months
following issuance and have a term of three years from the issuance date. The securities being sold to the Company director participating
in the offering are being issued pursuant to the Company's 2021 Equity Incentive Plan. The private placement is expected to close
on or about October 1, 2025, subject to the satisfaction of customary closing conditions.
gross proceeds from the offering are expected to be approximately $2.25 million, prior to offering expenses payable by the Company. The
Company intends to use the net proceeds from the offering for to fund the execution of Step 1 of Part C of the Phase II trial THIO -101
and for working capital.
securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the
"Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants,
have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares
of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable
exemption from the registration requirements of the Securities Act and such applicable state securities laws.
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.
MAIA Biotechnology, Inc.
is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with
novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is
ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients
with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements
of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and
unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance
or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might,"
"will," "should," "could," "expect," "plan," "anticipate," "believe,"
"estimate," "project," "intend," "future," "potential," or "continue,"
and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that
statements are not forward-looking. For example, all statements we make regarding (i) completion of the private placement, (ii) the initiation,
timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (iii) our ability
to advance product candidates into, and successfully complete, clinical studies, (iv) the timing or likelihood of regulatory filings and
approvals, (v) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process,
(vi) the rate and degree of market acceptance of our product candidates, (vii) the size and growth potential of the markets for our product
candidates and our ability to serve those markets, and (viii) our expectations regarding our ability to obtain and maintain intellectual
property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions
and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking
statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other
factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any
forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release,
unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us"
refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact